These drugs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications .
The serotonergic , noradrenergic and GABAergic pathways play a major role in the fear network and in the physiopathology of PD .
INTRODUCTION Panic disorder ( PD ) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks .
PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide .
PD should be treated effectively as soon as the symptoms emerge because the longer these patients remain without treatment , the worse the prognosis will be .
SSRIs and SNRIs are the first-line compounds in the treatment of PD .
Open‐Label Support for Duloxetine for the Treatment of Panic Disorder
Panic disorder with or without agoraphobia is a common , often chronic and refractory anxiety disorder . Although a number of pharmacotherapies are now indicated for panic disorder , many patients do not respond to available interventions . We hypothesized that duloxetine , a serotonin‐norepinephrine reuptake inhibitor ( SNRI ) that has greater initial noradrenergic effects than venlafaxine , would have broad efficacy for individuals with panic disorder . Fifteen individuals with panic disorder with or without agoraphobia received 8 weeks of open label duloxetine flexibly dosed from 60 to 120 mg per day . Duloxetine treatment result ed in significant anxiolysis as measured by the primary outcome measure , the Panic Disorder Severity Scale ( PDSS ) ( paired t(df ) = 4.02(14 ) , P= 0.0013 ) , as well as measures of generalized anxiety , depression and quality of life ( all P < 0.05 ) . Although definitive conclusions are limited due to its small open‐label nature , this first prospect i ve study provides preliminary support for the efficacy of duloxetine for panic disorder and suggests larger r and omized controlled study is warranted
These drugs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications .
The serotonergic , noradrenergic and GABAergic pathways play a major role in the fear network and in the physiopathology of PD .
INTRODUCTION Panic disorder ( PD ) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks .
PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide .
PD should be treated effectively as soon as the symptoms emerge because the longer these patients remain without treatment , the worse the prognosis will be .
SSRIs and SNRIs are the first-line compounds in the treatment of PD .